Also known as: Leerink Partners
Leerink Partners is a healthcare-focused investment bank providing strategic and capital markets advisory services. The firm positions itself as exclusively focused on healthcare clients and investors.
BioNTech faces mixed analyst views as Bernstein initiates with a cautious Market Perform rating, while the company secures FDA Fast Track designation for BNT113 and prepares for a shareholder vote on capital restructuring and leadership transition.
Arcturus Therapeutics completed three 28-day inhaled mRNA cohorts for cystic fibrosis that were well-tolerated and showed early biological signals. The company is preparing a 12-week Phase 2 study with tightened eligibility criteria and expanded enrollment into Europe and the Middle East.
The FDA informed uniQure that Phase 1/2 study data for AMT-130 in Huntington's disease is insufficient to support a biologics license application, recommending a prospective, randomized, double-blind, sham surgery-controlled study instead.
Edgewise Therapeutics and IDEAYA Biosciences released annual financial reports detailing clinical trial progress and strategic initiatives. Both companies are advancing multiple clinical-stage programs while managing significant operating expenses.
Rocket Pharmaceuticals will participate in two investor conferences in March 2026, with the CEO taking part in a fireside chat and management hosting investor meetings at both events.
Two financial services firms raised their price targets for Moderna in mid-February 2026, with RBC Capital increasing its target to $30 and Evercore ISI Group raising its target to $35, both maintaining neutral ratings.
Myriad Genetics will release its fourth quarter and full year 2025 financial results on February 23, 2026 after market close, followed by an earnings conference call at 4:30 pm ET.
